Join
Live feed
·
INSIDERFilingvia Quantisnow
Maze Therapeutics Inc. logo

Director Homcy Charles J converted options into 36,946 shares, increasing direct ownership by 104% to 58,047 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
MAZE· Maze Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MAZE (Maze Therapeutics Inc.) and more on Quantisnow.